Zacks Investment Research Downgrades Ziopharm Oncology Inc. (ZIOP) to Sell
Ziopharm Oncology Inc. (NASDAQ:ZIOP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Other equities research analysts have also recently issued research reports about the company. Mizuho reiterated a “neutral” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Griffin Securities reiterated a “buy” rating and issued a $21.00 price objective on shares of Ziopharm Oncology in a report on Monday, August 15th. Finally, Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. Ziopharm Oncology presently has an average rating of “Hold” and an average target price of $9.75.
Ziopharm Oncology (NASDAQ:ZIOP) opened at 6.87 on Tuesday. The firm has a 50-day moving average price of $5.74 and a 200 day moving average price of $5.88. The stock’s market cap is $896.51 million. Ziopharm Oncology has a 52-week low of $4.45 and a 52-week high of $13.74.
Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Wednesday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Ziopharm Oncology had a negative return on equity of 364.49% and a negative net margin of 2,276.89%. The business earned $1.60 million during the quarter, compared to analysts’ expectations of $1.45 million. During the same quarter last year, the business posted ($0.14) EPS. The business’s revenue was down 15.8% on a year-over-year basis. On average, analysts forecast that Ziopharm Oncology will post ($1.32) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZIOP. Fox Run Management L.L.C. bought a new position in Ziopharm Oncology during the second quarter worth $133,000. BlackRock Institutional Trust Company N.A. raised its position in Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock worth $22,601,000 after buying an additional 17,982 shares during the period. Schwab Charles Investment Management Inc. raised its position in Ziopharm Oncology by 2.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 468,322 shares of the biotechnology company’s stock worth $2,572,000 after buying an additional 9,672 shares during the period. Brown Advisory Inc. bought a new position in Ziopharm Oncology during the second quarter worth $1,166,000. Finally, California State Teachers Retirement System raised its position in Ziopharm Oncology by 4.9% in the second quarter. California State Teachers Retirement System now owns 254,849 shares of the biotechnology company’s stock worth $1,399,000 after buying an additional 11,934 shares during the period. 44.07% of the stock is owned by institutional investors.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Receive News & Stock Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related stocks with our FREE daily email newsletter.